Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is bronchial carcinoid (lung neuroendocrine tumor)?
Bronchial carcinoids are a type of lung tumor that arises from neuroendocrine cells lining the airways — hormone-sensing cells scattered through the bronchial walls. They are very different from common lung cancers: they grow slowly, are usually not linked to smoking, and often appear in younger adults. Because a carcinoid tends to sit in an airway, the first sign is frequently a cough, wheezing, repeated pneumonia in the same spot, or coughing up blood. A minority release hormones that cause flushing or other 'carcinoid syndrome' symptoms. Doctors divide them into typical carcinoids (low-grade, the great majority, excellent outlook) and atypical carcinoids (intermediate-grade, somewhat more likely to spread). Surgery to remove the tumor — ideally while sparing as much healthy lung as possible — cures most patients. For tumors that have spread, a powerful tool is peptide receptor radionuclide therapy (PRRT), which uses a radioactive molecule that attaches to the tumor's somatostatin receptors and irradiates it from the inside.
The main types
Doctors group bronchial carcinoid (lung neuroendocrine tumor) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Typical carcinoid (low-grade) | The large majority. Slow-growing, rarely spreads, and usually cured by surgery alone. Excellent long-term outlook. |
| Atypical carcinoid (intermediate-grade) | Less common and somewhat more aggressive, with a higher chance of reaching lymph nodes or distant sites. Watched and treated more closely. |
| Central vs. peripheral | Central carcinoids grow in the large airways near the lung's center (causing cough and blockage); peripheral ones sit out toward the lung edge and are often found by chance on a scan. |
Staging, in plain terms
Bronchial carcinoids are staged with the same tumor-node-metastasis (TNM) system as other lung cancers, but the grade — typical or atypical, based on how fast cells divide — is just as important for predicting behavior.
| Lung neuroendocrine TNM + grade (typical vs. atypical) | What it generally means |
|---|---|
| Stage I–II (localized) | The tumor is confined to the lung, possibly with a nearby node. Surgery removes it and cures the great majority — especially typical carcinoids. |
| Stage III (regional nodes) | The tumor has reached lymph nodes in the chest. Surgery is still often possible, sometimes with additional therapy afterward. |
| Stage IV (metastatic) | The tumor has spread beyond the chest, most often to the liver or bone. Treatment shifts to controlling growth with somatostatin analogs, PRRT, and other systemic options. |
| Grade (typical vs. atypical) | Typical carcinoids divide slowly and have the best outlook; atypical carcinoids divide faster and carry a higher risk of spread, which influences how aggressively they are treated and followed. |
The standard of care
Bronchial Carcinoid (Lung Neuroendocrine Tumor) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the main cure)
Removing the tumor — by taking out a segment, a lobe, or sleeving out an airway tumor while saving lung — cures most localized carcinoids. Lymph nodes are sampled to check for spread.
Somatostatin analogs
Drugs like octreotide and lanreotide can slow tumor growth and calm hormone symptoms in tumors that carry somatostatin receptors, often the first systemic step for advanced disease.
PRRT (radiation from within)
For receptor-positive tumors that have spread, lutetium-177 dotatate delivers radiation directly to the tumor cells, controlling growth and easing symptoms with relatively mild side effects.
External radiation & other systemic therapy
Focused external radiation can treat tumors that can't be removed or painful spread to bone; targeted drugs and chemotherapy are used in selected advanced cases.
How radiation treatment works
Radiation damages the DNA inside tumor cells so they can no longer divide. Bronchial carcinoids offer a unique advantage: their cells carry receptors that grab a specific molecule, so doctors can attach a radioactive atom to that molecule and inject it. The treatment — called PRRT — circulates through the body, sticks to carcinoid cells wherever they hide, and delivers its radiation from point-blank range while largely sparing normal tissue. When ordinary external radiation is needed instead, modern image-guided beams shape the dose tightly around a lung tumor or a painful spot of spread. All of these are painless and, in the case of PRRT, any radioactivity clears from the body over a few days.
The main ways radiation is delivered for bronchial carcinoid (lung neuroendocrine tumor):
Peptide receptor radionuclide therapy (PRRT)
A radioactive form of lutetium is attached to a molecule that locks onto the tumor's somatostatin receptors. Given through a vein, it travels to the carcinoid cells wherever they are and irradiates them from the inside, sparing most healthy tissue.
DOTATATE PET imaging
A scan using the same receptor-seeking molecule lights up carcinoid cells throughout the body. It both finds hidden spread and shows whether a tumor will respond to PRRT.
External-beam radiation (SBRT/IMRT)
Precisely shaped or stereotactic x-ray beams treat a lung tumor in someone who can't have surgery, or a painful area of spread, over a few focused painless sessions.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
PRRT for lung neuroendocrine tumors (Mayo, 2025): A multi-site analysis presented at the 2025 World Conference on Lung Cancer reported median overall survival of about 35.5 months for typical and 19.8 months for atypical bronchial carcinoids treated with lutetium-177 dotatate, with no severe (grade 3+) side effects.[1]
Mayo Clinic BP-NET analysis, WCLC 2025 (OncLive)
Lutetium-177 in lung neuroendocrine tumors: Reviews and trial data show PRRT produces partial responses and durable disease control in advanced bronchopulmonary neuroendocrine tumors, supporting its growing role for receptor-positive disease.[2]
Lutetium-177 literature review, PMC6443107
Australian PRRT experience in lung NETs: A clinical series reported meaningful tumor control and symptom relief from PRRT in lung neuroendocrine tumors, with a favorable safety profile.[3]
Australian PRRT experience, PMC7343632
Common questions
Is a bronchial carcinoid the same as lung cancer? It's a type of lung tumor, but it behaves very differently from common lung cancers. Carcinoids are neuroendocrine tumors that usually grow slowly, are not caused by smoking, and have a much better outlook — most are cured with surgery.
What is PRRT and will I be radioactive? PRRT is a treatment that attaches radiation to a molecule which homes in on your tumor's receptors, irradiating the cancer from the inside. You'll carry a small amount of radioactivity for a few days, so your team gives simple precautions, but it clears on its own.
What's the difference between typical and atypical carcinoid? Typical carcinoids — the great majority — grow slowly and rarely spread, with an excellent outlook. Atypical carcinoids divide faster and are more likely to reach lymph nodes or other organs, so they're treated and followed more closely.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.